U.S. First Lady Melania Trump underwent an interventional radiology embolization procedure to treat a benign kidney condition, according to a statement from the White House Press Office.

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and objective assessment of stroke, stent thrombosis and bleeding risk in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). The data was presented as late-breaking clinical science at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the selection of specific categories of devices when endovascular therapy (EVT) is indicated. The purpose of this document, which is the first of its kind, is to provide a review of comparative effectiveness data, including safety and efficacy of femoral-popliteal (FP) devices. The document also provides clinicians with guidance and recommendations for device selection when these devices are intended as the definitive or adjunctive therapy.

Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary intervention (PCI) will allow for flexibility in length of stay while ensuring patient safety. The guidelines were published in early-view online in Catheterization and Cardiovascular Interventions, the official journal of the Society for Cardiovascular Angiography and Interventions (SCAI).

No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018. #SCAI, #SCAI2018,

May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal complications undergoing angiography had no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function. The results were presented at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used for patients with multivessel disease (MVD) and acute myocardial infarction (AMI) with cardiogenic shock (CS). In a new study, percutaneous coronary intervention (PCI) of the culprit vessel was associated with improved outcomes, despite the majority of these patients having multivessel disease (MVD).

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin disease, can help reduce coronary plaque. The authors found that not only do the treatments reduce the volume of the plaque, but also the plaque becomes less inflammatory over time, harboring fewer characteristics prone to rupture and cause a heart attack. It is the first-in-human observational study demonstrating that treating remote inflammation in the body can modulate coronary disease.
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femoral transcatheter aortic valve replacement (TF-TAVR) procedure may be associated with negative short and long-term outcomes. The authors, for the first time, report a significant decline in the rates of delayed discharge; and identified independent predictors of both delayed and early discharge post TAVR.

May 14, 2018 – One-year outcomes of patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) treated with zotarolimus-eluting stents (ZES) showed positive outcomes in the PERSPECTIVE trial.[1] Results of the study were presented as late-breaking clinical science at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict paravalvular leak (PVL) in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL. To address this risk, the study used 3-D printing technology to help confirm and detect the location of the leak.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now